NEU 0.35% $20.17 neuren pharmaceuticals limited

Ann: Neuren appoints Vice President, Corporate Development, page-16

  1. 2,167 Posts.
    lightbulb Created with Sketch. 571
    Wow, $124m US combined and further double digit royalties on net sales!

    And based on peak sales of $500m combined US/Europe x5 countries.

    Neu have this forecast in US licensing alone with potential patients 10,000. (5,000 identified)

    ROW license has potential patents 50,000 (7,000 identified)

    Peak sales in ROW licence for Neu could be at least double US @ $1B+, maybe 4-5 times US market.


 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.